Vaccination in Patients with Inflammatory Bowel Diseases
- 21 January 2020
- journal article
- review article
- Published by S. Karger AG in Digestion
- Vol. 101 (SUPPL 1), 58-68
- https://doi.org/10.1159/000503253
Abstract
During the course of disease, a majority of inflammatory bowel disease (IBD) patients requires long-term immunosuppressive therapy with either immunomodulatory agents, biologics, or newer immunosuppressive therapies such as Vedolizumab, a selective alpha 4 beta 7 inhibitor, Ustekinumab, an IL 12/23 p40 inhibitor, or the Janus kinase inhibitor Tofacitinib. Due to this, they are at increased risk for infectious diseases, many of which are possible to prevent by vaccination. This review focuses on recommended vaccinations in IBD patients and stresses special issues which have to be paid attention to. The aim of the review is to increase gastroenterologists' awareness of the importance of vaccination and to stress why especially the gastroenterologist should assess the vaccination status of the patient and initiate vaccination as soon as diagnosis is established.This publication has 78 references indexed in Scilit:
- Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient SampleClinical and Experimental Gastroenterology, 2013
- Increased Risk of Pneumonia Among Patients With Inflammatory Bowel DiseaseThe American Journal of Gastroenterology, 2013
- Increased risk of herpes zoster among 108 604 patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2012
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryThe American Journal of Gastroenterology, 2012
- Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infectionJournal of Viral Hepatitis, 2012
- The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelinesScandinavian Journal of Gastroenterology, 2011
- Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of PersistenceJNCI Journal of the National Cancer Institute, 2010
- Suboptimal Rates of Cervical Testing Among Women With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2009
- The effect of anti-tumour necrosis factor treatment on the antibody response to influenza vaccinationAnnals Of The Rheumatic Diseases, 2007
- Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxisGut, 2004